Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | F12 | P00748 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.43 |
| ▸ | C1S | P09871 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8141954 | 0.77 | GAA (0.41) | F2F10F12F7F3 | |
| SCHEMBL6397389 | 0.77 | F2 (0.41) | F2F10F12F7F3 | |
| SCHEMBL21129520 | 0.77 | F2 (0.41) | F2F10F12F7F3 | |
| SCHEMBL456940 | 0.76 | THRB (0.54) | PKMKMT2AGAAMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL28552304 | 0.76 | BLM (0.43) | F2F10F12F7F3 | |
| SCHEMBL5728635 | 0.74 | ABAT (0.47) | BLMKMT2AGAAMAPTKDM4E | |
| SCHEMBL3557897 | 0.73 | F2 (0.52) | F2F10F12F7F3 | |
| SCHEMBL948542 | 0.73 | GAA (0.68) | PRSS1RECQLGAAMAPTHPGD | |
| SCHEMBL17826872 | 0.72 | MAOA (0.39) | F2F10F12F7F3 | |
| Hydrochloric Acid SCHEMBL11625721 | 0.72 | ABAT (0.46) | BLMKMT2AGAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105744966-A | ANTI-THROMBOTIC MATERIAL | 东丽株式会社 | 2016-07-06 | — | — | CN | disclosed |
| US-7449446-B2 | Combination product comprising melagatran and dexamethasone | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| US-20080113960-A1 | Combinations comprising a low molecular weight thrombin inhibitor and a prodrug of a low molecular weight thrombin inhibitor | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| EP-1886691-A2 | A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug | AstraZeneca AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1200118-B1 | A PHARMACEUTICAL FORMULATION COMPRISING MEGALATRAN AND ITS PRODRUG | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| US-20060287249-A1 | Crystalline forms | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| EP-1196431-B1 | A SUBSTANTIALLY CRYSTALLINE FORM OF MELAGATRAN | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1294395-B1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR VIIa INHIBITOR | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| EP-1294394-B1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR Xa INHIBITOR | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20060074080-A1 | Combination product comprising melagatran and an anti-arrhythmic oxabispidenes | ASTRAZENECA AB (SE) | 2006-04-06 | — | — | US | disclosed |
| US-6440939-B2 | THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-08-27 | — | — | US | disclosed |
| WO-2002051445-A2 | AN ORAL AND PARENTERAL PHARMACEUTICAL FORMULATION COMPRISING A LOW MOLECULAR WEIGHT THROMBIN INHIBITOR PRODRUG | ABBOTT GMBH & CO. KG (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1200118-A1 | A PHARMACEUTICAL FORMULATION COMPRISING A LOW MOLECULAR WEIGHT THROMBIN INHIBITOR AND ITS PRODRUG | AstraZeneca AB (SE) | 2002-05-02 | — | — | EP | disclosed |
| EP-1196431-A1 | A SUBSTANTIALLY CRYSTALLINE FORM OF MELAGATRAN | AstraZeneca AB (SE) | 2002-04-17 | — | — | EP | disclosed |
| US-20010023244-A1 | New crystalline forms | ASTRA AKTIEBOLAG | 2001-09-20 | — | — | US | disclosed |
| EP-1107980-A1 | CRYSTALLINE FORMS OF EtO 2?C-CH 2?-($i(R))Cgl-Aze-Pab-OH | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| US-6225287-B1 | INHIBITION OF THROMBIN; EASE OF HANDLING; IMPROVED CHEMICAL AND SOLID STATE STABILITY; CRYSTALLISED IN GOOD YIELDS, HIGHER PURITY, IN LESS TIME, MORE CONVENIENTLY, AND AT A LOWER COST, | ASTRA AKTIEBOLAG (SE) | 2001-05-01 | — | — | US | disclosed |
| WO-2001002426-A1 | A SUBSTANTIALLY CRYSTALLINE FORM OF MELAGATRAN | ASTRAZENECA AB (SE) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000064470-A1 | A PHARMACEUTICAL FORMULATION COMPRISING A LOW MOLECULAR WEIGHT THROMBIN INHIBITOR AND ITS PRODRUG | ASTRAZENECA AB (SE) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000014110-A1 | CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH | ASTRAZENECA AB (SE) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074080-A1 | Combination product comprising melagatran and an anti-arrhythmic oxabispidenes | O60361, KCNH1, WNT3A | F2 120/4885F10 1149/4885F12 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.